Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity
Boehringer Ingelheim obtains global rights to glucagon/GLP-1 dual agonists, including ZP2929, Zealand Pharma’s lead drug candidate in this class
17-Jun-2011 -
Zealand Pharma and Boehringer Ingelheim jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.As part of the agreement, Boehringer Ingelheim ...
Boehringer Ingelheim
drug development
obesity
+1